Benjamin Kong
Angel Investor
San Francisco, United States
Benjamin Kong is a Canadian investor backing early-stage transformative startups in Space, Biotech, Life Sciences, AI, Longevity, and Blockchain. He started investing in 2014 and has since funded over 50 startups and 3 VC funds. Recent early stage investments include Luminous Computing, Orbit Fab, Relativity Space, Swarm, TransAstra, RadianAerospace, Volumetric, OISIN, OncoSenX, Aegis BioDefense, Excision Biotherapeutics, MAIA Biotechnology, Ashvattha Therapeutics, ZenGo, Coinbase, Algorand, Oasis Labs, Arweave.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Benjamin Kong invests in
Stages Benjamin Kong invests in
Countries Benjamin Kong invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $750k–$8.7M
Investment Focus
Industry
- Biotechnology 5 (28%)
- Blockchain 4 (22%)
- Cryptocurrency 3 (17%)
- FinTech 2 (11%)
- Aerospace 2 (11%)
Stage
- Seed 7 (39%)
- Pre-Seed 2 (11%)
- Funding Round 2 (11%)
- Venture - Series Unknown 2 (11%)
- Series A 1 (6%)
Country
- United States 11 (61%)
- Israel 1 (6%)
- United Kingdom 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Radian Aerospace (Radian) is disrupting the aerospace industry with a next generation aerospace vehicle that is the world’s first fully reusable horizontal takeoff and landing, single-stage to orbit spaceplane, delivering people and light cargo to low earth orbit (LEO) and multiple terrestrial destinations with aircraft-like operations. | Pre-Seed / May 01, 2020 | ||
| Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editingtherapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world. | Dec 20, 2019 | ||
| Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editingtherapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world. | $750K / Seed / Dec 20, 2019 | ||
| Volumetric is an advanced biomaterials and biofabrication company that develops a 3D bioprinting platform intended to create materials with living cells with applications in biomaterials, cancer research, and human organ replacements. | $1.8M / Seed / Nov 19, 2019 | ||
| MAIA Biotechnology is dedicated to developing targeted cancer therapies with novel mechanisms of action that are intended to meaningfully improve and extend the lives of patients with cancer. Telomerase is present in 90% of human cancer cells and contributes significantly to proliferative abilities and immortality of cancer cells. It is eitherabsent or shows low activity in normal cells. THIO(6-thio-dG) is recognized by telomerase and incorporated into telomeres. Once incorporated, it compromises telomere structure and function, leading to ‘uncapping’ of the chromosome ends resulting in rapid tumor cell death. | $1.5M / Seed / Oct 09, 2019 | ||
| MAIA Biotechnology is an immuno-oncology company that focuses on developing first-in-class drugs with novel mechanisms. | $1.5M / Seed / Oct 09, 2019 | ||
| Relativity Space is an aerospace company that designs, develops, and builds 3D-printed rockets. a vertically integrated technology platform, Relativity is at the forefront of an inevitable shift toward software-defined manufacturing by fusing 3D printing, artificial intelligence, and autonomous robotics. It offers a radically simplified supplychain, building a rocket with 100x fewer parts in less than 60 days. Relativity Space is backed by leading investors including Bond, Tribe Capital, Playground Global, Y Combinator, Social Capital, and Mark Cuban. | $140M / Series C / Oct 01, 2019 | ||
| ZenGo is a developer of a non-custodial digital currency wallet designed to make the global crypto economy more accessible. | Seed / Sep 05, 2019 | ||
| OncoSenX is a developer of transient gene therapies designed for solid tumors. The company's therapy delivers plasmid DNA with a novel lipid nanoparticle that selectively kills cancerous cells based on their transcriptional activity, providing cancer patients, doctors and medical care professionals with a less invasive and more preciseintervention for this complex and devastating disease. | $3M / Pre-Seed / Jul 08, 2019 | ||
| Coinbase is an online platform for digital currency transactions, enabling merchants, consumers, and traders to buy, sell, and store cryptocurrencies. The company provides Bitcoin wallet services, allowing users to manage digital assets and conduct transactions. Coinbase offers merchant payment processing tools, supporting businesses in integratingcryptocurrency payments. It facilitates secure digital currency exchanges, assisting users in navigating blockchain-based financial transactions. | $300M / Series E / Oct 30, 2018 | ||
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Benjamin Kong invest in?
Benjamin Kong invests primarily in Biotechnology, Blockchain and Cryptocurrency startups, most often at Seed and Pre-Seed stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Benjamin Kong's check size?
Benjamin Kong typically joins rounds of $750k–$8.7M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Benjamin Kong participates in.
How do I contact Benjamin Kong?
Public channels for Benjamin Kong include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Benjamin Kong last invest?
The most recent investment recorded for Benjamin Kong closed in May 2020. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
